Sun Qianqian, Li Weiqing, Liu Taorui, Guo Huiqin
Department of Thoracic Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Front Oncol. 2022 May 26;12:916681. doi: 10.3389/fonc.2022.916681. eCollection 2022.
The incidence of lung cancer is high and about 75% of the patients with lung cancer are found in the middle and advanced stage, which has a limited treatment strategy. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. In this article, we delineate the treatment process of a middle-aged male patient with advanced-stage lung cancer to explain the significance of individualized chemotherapy combined with immunotherapy and surgery. This patient has extensive bone metastasis with PS scores of 2. After nine cycles of preoperative neoadjuvant chemotherapy, surgery, and two cycles of postoperative adjuvant chemotherapy, the patient achieved complete response (CR) and his PS score was 0. Although there is a standard chemotherapy regimen for lung adenocarcinoma, the treatment effect varies because of individual differences. Comprehensive analysis of the characteristics of patients through a variety of means to develop a precise individualized chemotherapy plan will be a major direction of lung cancer treatment in the future. Additionally, surgical treatment for advanced lung cancer patients after chemotherapy can effectively reduce the primary lesion and prolong the survival time of patients.
肺癌的发病率很高，约75%的肺癌患者在中晚期被发现，其治疗策略有限。非小细胞肺癌（NSCLC）约占所有肺癌的85%。在本文中，我们描述了一名晚期肺癌中年男性患者的治疗过程，以解释个体化化疗联合免疫治疗及手术的意义。该患者有广泛骨转移，PS评分为2。经过九个周期的术前新辅助化疗、手术及两个周期的术后辅助化疗后，患者达到完全缓解（CR），其PS评分为0。虽然肺腺癌有标准的化疗方案，但由于个体差异，治疗效果各不相同。通过多种手段综合分析患者特征以制定精准的个体化化疗方案将是未来肺癌治疗的主要方向。此外，化疗后对晚期肺癌患者进行手术治疗可有效缩小原发灶并延长患者生存时间。
